Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
Actuate Therapeutics, Inc. (ACTU)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$0.33-11.60%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for ACTU yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Sufficient capital to fund operations and trials | The company raised capital through debt in 2025 to fund growth. | Under Pressure | Capital depletion or failure to raise funds by end 2026 | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Nov 12, 2026
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is a speculative development-stage company, not an established earnings compounder. The long-term thesis is in a watch state: management has stated a priority to advance oral elraglusib, but the evidence snapshot does not show clinical delivery, and overall confidence is low.
The supplied evidence does not include a valuation measure or specific market expectations, so how much optimism or risk is already reflected cannot be assessed. Losses and funding needs are clear, while an October financing announcement cited expected gross proceeds but does not establish net proceeds or a longer operating runway.
Near term, operating losses continued in both reported quarters, though the reported loss was smaller in Q2 than Q1. ACTU also faces elevated risk of a next-quarter earnings miss, and a recent delisting-rule notice adds to the near-term risks. The healthcare sector backdrop has improved, but it does not resolve the company-specific funding and clinical execution questions.
Over the next few quarters, the thesis depends on evidence of progress in the oral elraglusib program and on whether ACTU secures enough capital to support operations. A guidance cut or further weakening in jobs data would add risk; continued strength among healthcare bellwethers could support the sector backdrop, but would not establish ACTU's own progress.
For the 1-3 year view, ACTU remains a highly uncertain, loss-making development story with limited proof of clinical execution and unresolved funding needs. The evidence supports a cautious watch state, not a settled long-term thesis. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| Actuate is advancing clinical trials for cancer treatments. |
| Intact |
| Failure to achieve key clinical milestones or negative trial results in 2026 |
Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Reduction in net loss and improvement in EPS | A supporting condition in Actuate Therapeutics, Inc.'s published investment case. The stated target is EPS loss narrows or stabilizes above -$0.78 in FY26. | Broken | EPS loss worsens beyond -$0.78 in FY26 | Diluted EPS: $-0.20 per share FY2026-Q2; GAAP. Published target: EPS loss narrows or stabilizes above -$0.78 in FY26. Annual target cannot be compared with a quarterly or TTM observation. Aug 14, 2026-0.2 USD/share · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$-0.85 → $-0.66 · observed estimates
$0.01B → $0.01B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $-0.85 | $6,235,000 | 3 / 3 |
| 2026-07-25 | $-0.85 | $6,235,000 | 3 / 3 |
| 2026-07-26 | $-0.85 | $6,235,000 | 3 / 3 |
| 2026-07-27 | $-0.85 | $6,235,000 | 3 / 3 |
| 2026-07-28 | $-0.85 | $6,235,000 | 3 / 3 |
| 2026-07-29 | $-0.85 | $6,235,000 | 3 / 3 |
| 2026-07-30 | $-0.85 | $0 | 4 / 4 |
| 2026-07-31 | $-0.85 | $0 | 4 / 4 |
| 2026-08-01 | $-0.85 | $0 | 4 / 4 |
| 2026-08-02 | $-0.85 | $0 | 4 / 4 |
| 2026-08-03 | $-0.85 | $0 | 4 / 4 |
| 2026-08-04 | $-0.85 | $0 | 4 / 4 |
| 2026-08-05 | $-0.85 | $0 | 4 / 4 |
| 2026-08-06 | $-0.85 | $0 | 4 / 4 |
| 2026-08-07 | $-0.85 | $6,235,000 | 3 / 3 |
| 2026-08-08 | $-0.85 | $0 | 4 / 4 |
| 2026-08-09 | $-0.85 | $0 | 4 / 4 |
| 2026-08-10 | $-0.85 | $0 | 4 / 4 |
| 2026-08-11 | $-0.85 | $6,235,000 | 3 / 3 |
| 2026-08-12 | $-0.85 | $6,235,000 | 3 / 3 |
| 2026-08-13 | $-0.85 | $0 | 4 / 4 |
| 2026-08-14 | $-0.85 | $6,235,000 | 3 / 3 |
| 2026-08-15 | $-0.85 | $6,235,000 | 3 / 3 |
| 2026-08-16 | $-0.85 | $6,235,000 | 3 / 3 |
| 2026-08-17 | $-0.85 | $6,235,000 | 3 / 3 |
| 2026-08-18 | $-0.85 | $6,235,000 | 3 / 3 |
| 2026-08-19 | $-0.85 | $6,235,000 | 3 / 3 |
| 2026-08-20 | $-0.72 | $6,235,000 | 3 / 3 |
| 2026-08-21 | $-0.72 | $6,235,000 | 3 / 3 |
| 2026-08-22 | $-0.73 | $6,235,000 | 3 / 3 |
| 2026-08-23 | $-0.73 | $6,235,000 | 3 / 3 |
| 2026-08-24 | $-0.73 | $6,235,000 | 3 / 3 |
| 2026-08-25 | $-0.73 | $6,235,000 | 3 / 3 |
| 2026-08-26 | $-0.73 | $6,235,000 | 3 / 3 |
| 2026-08-27 | $-0.73 | $6,235,000 | 3 / 3 |
| 2026-08-28 | $-0.73 | $6,235,000 | 3 / 3 |
| 2026-08-29 | $-0.73 | $6,235,000 | 3 / 3 |
| 2026-08-30 | $-0.73 | $6,235,000 | 3 / 3 |
| 2026-08-31 | $-0.73 | $6,235,000 | 3 / 3 |
| 2026-09-01 | $-0.73 | $6,235,000 | 3 / 3 |
| 2026-09-02 | $-0.73 | $6,235,000 | 2 / 2 |
| 2026-09-03 | $-0.73 | $6,235,000 | 2 / 2 |
| 2026-09-04 | $-0.73 | $6,235,000 | 2 / 2 |
| 2026-09-05 | $-0.66 | $6,235,000 | 2 / 2 |
| 2026-09-06 | $-0.66 | $6,235,000 | 2 / 2 |
| 2026-09-07 | $-0.66 | $6,235,000 | 2 / 2 |
| 2026-09-08 | $-0.66 | $6,235,000 | 2 / 2 |
| 2026-09-09 | $-0.66 | $6,235,000 | 2 / 2 |
| 2026-09-10 | $-0.66 | $6,235,000 | 2 / 2 |
| 2026-09-11 | $-0.66 | $6,235,000 | 2 / 2 |
| 2026-09-12 | $-0.66 | $6,235,000 | 2 / 2 |
| 2026-09-13 | $-0.66 | $6,235,000 | 2 / 2 |
| 2026-09-14 | $-0.66 | $6,235,000 | 2 / 2 |
| 2026-09-15 | $-0.66 | $6,235,000 | 2 / 2 |
| 2026-09-16 | $-0.66 | $6,235,000 | 2 / 2 |
| 2026-09-17 | $-0.66 | $6,235,000 | 2 / 2 |
| 2026-09-18 | $-0.66 | $6,235,000 | 2 / 2 |
| 2026-09-19 | $-0.66 | $6,235,000 | 2 / 2 |
| 2026-09-20 | $-0.66 | $6,235,000 | 2 / 2 |
| 2026-09-21 | $-0.66 | $6,235,000 | 2 / 2 |
| 2026-09-22 | $-0.66 | $6,235,000 | 2 / 2 |
| 2026-09-23 | $-0.66 | $6,235,000 | 2 / 2 |
| 2026-09-24 | $-0.66 | $6,235,000 | 2 / 2 |
| 2026-09-25 | $-0.66 | $6,235,000 | 2 / 2 |
| 2026-09-26 | $-0.66 | $6,235,000 | 2 / 2 |
| 2026-09-27 | $-0.66 | $6,235,000 | 2 / 2 |
| 2026-09-28 | $-0.66 | $6,235,000 | 2 / 2 |
| 2026-09-29 | $-0.66 | $6,235,000 | 2 / 2 |
| 2026-09-30 | $-0.66 | $6,235,000 | 2 / 2 |
| 2026-10-01 | $-0.66 | $6,235,000 | 2 / 2 |
| 2026-10-02 | $-0.66 | $6,235,000 | 2 / 2 |
| 2026-10-03 | $-0.66 | $6,235,000 | 2 / 2 |
| 2026-10-04 | $-0.66 | $6,235,000 | 2 / 2 |
| 2026-10-05 | $-0.66 | $6,235,000 | 2 / 2 |
| 2026-10-06 | $-0.66 | $6,235,000 | 2 / 2 |
| 2026-10-07 | $-0.66 | $6,235,000 | 2 / 2 |
| 2026-10-08 | $-0.66 | $6,235,000 | 2 / 2 |
| 2026-10-09 | $-0.66 | $6,235,000 | 2 / 2 |
| 2026-10-10 | $-0.66 | $6,235,000 | 2 / 2 |
| 2026-10-11 | $-0.66 | $6,235,000 | 2 / 2 |
| 2026-10-12 | $-0.66 | $6,235,000 | 2 / 2 |
| 2026-10-13 | $-0.66 | $6,235,000 | 2 / 2 |
| 2026-10-14 | $-0.66 | $6,235,000 | 2 / 2 |
| 2026-10-15 | $-0.66 | $6,235,000 | 2 / 2 |
| 2026-10-16 | $-0.66 | $6,235,000 | 2 / 2 |
| 2026-10-17 | $-0.66 | $6,235,000 | 2 / 2 |
| 2026-10-18 | $-0.66 | $6,235,000 | 2 / 2 |
| 2026-10-19 | $-0.66 | $6,235,000 | 2 / 2 |
| 2026-10-20 | $-0.66 | $6,235,000 | 2 / 2 |
| 2026-10-21 | $-0.66 | $6,235,000 | 2 / 2 |
| 2026-10-22 | $-0.66 | $6,235,000 | 2 / 2 |
| 2026-10-23 | $-0.66 | $6,235,000 | 2 / 2 |
| 2026-10-24 | $-0.66 | $6,235,000 | 2 / 2 |
| 2026-10-25 | $-0.66 | $6,235,000 | 2 / 2 |
| 2026-10-26 | $-0.66 | $6,235,000 | 2 / 2 |
| 2026-10-27 | $-0.66 | $6,235,000 | 2 / 2 |
| 2026-10-28 | $-0.66 | $6,235,000 | 2 / 2 |
| 2026-10-29 | $-0.66 | $6,235,000 | 2 / 2 |
| 2026-10-30 | $-0.66 | $6,235,000 | 2 / 2 |
| 2026-10-31 | $-0.66 | $6,235,000 | 2 / 2 |
| 2026-11-01 | $-0.66 | $6,235,000 | 2 / 2 |
| 2026-11-02 | $-0.66 | $6,235,000 | 2 / 2 |
| 2026-11-03 | $-0.66 | $6,235,000 | 2 / 2 |
| 2026-11-04 | $-0.66 | $6,235,000 | 2 / 2 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 3 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell
Recent actions · Oct 6–Nov 4 · 0 recorded
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.